Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DEA agent to FDA safety panel: Hydrocodone combos are 'killing us'

This article was originally published in Scrip

Executive Summary

Drug safety advisers to the US FDA heard arguments from both ends of the spectrum on 24 January about the impact to patients and society if hydrocodone combination medicines, like Vicodin (acetaminophen-hydrocodone), are moved from Schedule III to the more restrictive Schedule II – or "up-scheduled" – under authorities granted to the agency by the 1970 US Controlled Substances Act (CSA).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts